{"id":441578,"date":"2021-02-23T07:03:19","date_gmt":"2021-02-23T12:03:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=441578"},"modified":"2021-02-23T07:03:19","modified_gmt":"2021-02-23T12:03:19","slug":"cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/","title":{"rendered":"Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., Feb.  23, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RMKWK3NURsNz1Au8sLPcmm5B156fEfqscPieFZkGYYdLsIeFFGb0c_5hWQM1ds02FpFRTK_2vB0Ij0kbFn1FZziDtgua1ycL2jPwsHx55eA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Cerevel Therapeutics<\/a> (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to\u00a0treat\u00a0neuroscience\u00a0diseases, today announced that the company will participate in the upcoming Cowen 41st Annual Health Care Conference.<\/p>\n<p align=\"justify\">\n        <strong>Date<\/strong>: Wednesday, March 3, 2021<br \/><strong>Format<\/strong>: Presentation at 11:00 a.m. EST<\/p>\n<p align=\"justify\">The live webcast of the presentation can be accessed on the investor relations section of the Cerevel Therapeutics website <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lgGqBNJkG8tLEcaIIvDDjCUkT4tDGQxL1-_5jkYvT8pq6IMuTXLUX7YZtfy9EsttWK_-vLCUl1vc_ET1v3re0YYURuxnwXrcHHn95GI30-M=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a>. A replay will be available in the same section of the company\u2019s website.<\/p>\n<p align=\"left\">\n        <strong>About Cerevel Therapeutics<\/strong><br \/>\n        <br \/>Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson\u2019s, epilepsy, schizophrenia and substance use disorder. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2fEY4_dOBNdiqWG4L-C3LHtdXFO3IkFyJkeOQFYAbkEsUGpVohWHRqFZBk5bjHlLILukqXo8sqAR13XXySsreA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.cerevel.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Special Note Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>\n        <em>This press release contains forward-looking statements that are based on management\u2019s beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201congoing\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about our participation in the upcoming Cowen 41st Annual Health Care Conference and the potential attributes and benefits of our product candidates. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, among others: that clinical trial results may not be favorable; uncertainties inherent in the product development process (including with respect to the timing of results and whether such results will be predictive of future results); the impact of COVID-19 on the timing, progress and results of ongoing or planned clinical trials; other impacts of COVID-19, including operational disruptions or delays or to our ability to raise additional capital; whether and when, if at all, our product candidates will receive approval from the FDA or other regulatory authorities, and for which, if any, indications; competition from other biotechnology companies; uncertainties regarding intellectual property protection; and other risks identified in our SEC filings, including those under the heading \u201cRisk Factors\u201d in our prospectus filed with the SEC on December 4, 2020. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.<\/em>\n      <\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Kate Contreras<br \/>W2O <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kEV3cYY3RUhoGS2L_RVyksugY4t8MgOwsyASwP2IimlH4zbUIOF8f0tydHTN_HAYh11qBsJPYKlYg0ZAKO3ySpF82j8Ecnwl1BypVYL_kL4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">kcontreras@w2ogroup.com <\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Matthew Calistri<br \/>Cerevel Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=blRs9-alzRDgJmyXJj9bnHBINfxbtFV1ICSWsB_IXfxEzKzkHbLeJQPEeCaAILx6T50uGFXpk3tBo8y3L6dVpqSFPHH-lnoxB3hxY9WqMbPoRCSPSghpz6y4nrGQrcCA\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">matthew.calistri@cerevel.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzM4OCMzOTg4NjA3IzIxOTU0MTM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/36540528-22fd-428c-8634-0b0452d0ce58\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to\u00a0treat\u00a0neuroscience\u00a0diseases, today announced that the company will participate in the upcoming Cowen 41st Annual Health Care Conference. Date: Wednesday, March 3, 2021Format: Presentation at 11:00 a.m. EST The live webcast of the presentation can be accessed on the investor relations section of the Cerevel Therapeutics website here. A replay will be available in the same section of the company\u2019s website. About Cerevel Therapeutics Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-441578","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to\u00a0treat\u00a0neuroscience\u00a0diseases, today announced that the company will participate in the upcoming Cowen 41st Annual Health Care Conference. Date: Wednesday, March 3, 2021Format: Presentation at 11:00 a.m. EST The live webcast of the presentation can be accessed on the investor relations section of the Cerevel Therapeutics website here. A replay will be available in the same section of the company\u2019s website. About Cerevel Therapeutics Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor &hellip; Continue reading &quot;Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-23T12:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzM4OCMzOTg4NjA3IzIxOTU0MTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference\",\"datePublished\":\"2021-02-23T12:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\\\/\"},\"wordCount\":722,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzM4OCMzOTg4NjA3IzIxOTU0MTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\\\/\",\"name\":\"Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzM4OCMzOTg4NjA3IzIxOTU0MTM=\",\"datePublished\":\"2021-02-23T12:03:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzM4OCMzOTg4NjA3IzIxOTU0MTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzM4OCMzOTg4NjA3IzIxOTU0MTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/","og_locale":"en_US","og_type":"article","og_title":"Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to\u00a0treat\u00a0neuroscience\u00a0diseases, today announced that the company will participate in the upcoming Cowen 41st Annual Health Care Conference. Date: Wednesday, March 3, 2021Format: Presentation at 11:00 a.m. EST The live webcast of the presentation can be accessed on the investor relations section of the Cerevel Therapeutics website here. A replay will be available in the same section of the company\u2019s website. About Cerevel Therapeutics Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor &hellip; Continue reading \"Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-23T12:03:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzM4OCMzOTg4NjA3IzIxOTU0MTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference","datePublished":"2021-02-23T12:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/"},"wordCount":722,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzM4OCMzOTg4NjA3IzIxOTU0MTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/","name":"Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzM4OCMzOTg4NjA3IzIxOTU0MTM=","datePublished":"2021-02-23T12:03:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzM4OCMzOTg4NjA3IzIxOTU0MTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzM4OCMzOTg4NjA3IzIxOTU0MTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-cowen-41st-annual-health-care-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=441578"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441578\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=441578"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=441578"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=441578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}